Obesity Today—June 16, 2026

This week’s Obesity update highlights clinical progress, oral therapy competition, care-delivery partnerships, access challenges, and population-health data.

In this Newsletter

Dive deeper

💉 Gan & Lee reports positive insulin and obesity pipeline data [1] [China • 12 Jun 2026]

https://www.prnewswire.com/news-releases/gan–lee-pharmaceuticals-achieves-significant-progress-in-its-dual-pipeline-for-metabolic-diseases–weekly-insulin-ludefen-gzr4-meets-primary-endpoint-in-phase-iii-clinical-trial-in-china-bofanglutide-meets-primary-endpoints–302794945.html
Context: SUPER-3 enrolled 596 adults with type 2 diabetes across 80 China sites over 26 weeks.
Key point: Insulin Ludefen (GZR4) beat insulin glargine U100 on HbA1c reduction, with no severe hypoglycemia reported in the Ludefen arm.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 Oral obesity-drug race intensifies across major pharma [2] [UK • 11 Jun 2026]

https://www.reuters.com/business/healthcare-pharmaceuticals/factbox-top-pharma-companies-work-launch-first-weight-loss-pill-2026-06-11/
Context: Reuters listed oral obesity programs from Novo Nordisk, Eli Lilly, Structure Therapeutics, Merck, AstraZeneca, Roche, Viking, Pfizer, Innovent, HuaDong, and Ascletis.
Key point: Novo Nordisk received UK approval for its oral Wegovy, while Lilly’s Orforglipron and several rivals advanced clinical or preclinical oral GLP-1 programs.
Implication: May influence prescriber choice and payer reviews pending full data.

🏥 InBody builds GLP-1-linked China pharmacy infrastructure [3] [China • 10 Jun 2026]

https://en.sedaily.com/finance/2026/06/10/inbody-partners-with-global-pharma-to-tap-chinas-glp-1
Context: InBody’s China unit will supply analyzers, training, and installation for in-pharmacy weight-management centers.
Key point: The undisclosed pharma partner is using InBody devices to monitor body composition around GLP-1 use and obesity counseling.
Implication: May expand screening, initiation, and follow-up at scale.

📈 Innovent’s mazdutide data published in JAMA [4] [China • 13 Jun 2026]

https://www.chinadaily.com.cn/a/202606/13/WS6a2d3a66a310986e2b45fc85.html
Context: The study evaluated once-weekly mazdutide 9 mg in Chinese adults with obesity.
Key point: Innovent Biologics reported mean weight reduction above 20%, cardiometabolic improvements, and a generally safe profile. Implication: May influence prescriber choice and payer reviews pending full data.

🚧 South Korea sees surge in illegal anti-obesity drug imports [5] [South Korea • 09 Jun 2026]

https://www.khan.co.kr/en/article/202606090948007
Context: Kyunghyang Shinmun reported Korea Customs Service holds on anti-obesity drugs rose sharply in January–April 2026.
Key point: The report linked cross-border demand to price gaps for drugs such as Mounjaro between South Korea and Japan.
Implication: Introduces competition that may affect pricing and formulary access.

⚖️ South Korea adult obesity reaches new high [6] [South Korea • 14 Jun 2026]

http://koreabizwire.com/obesity-rates-reach-new-high-in-south-korea-as-lifestyle-risks-mount/353094
Context: Korea Disease Control and Prevention Agency data covered roughly 230,000 adults aged 19 and older.
Key point: South Korea’s adult obesity rate reached 34.4% in 2024, with men in their 30s and 40s above 50%.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

Why it matters

Oral obesity medicines are becoming a central competitive battleground for Novo Nordisk, Eli Lilly, and emerging GLP-1 developers.
China remains active across clinical development, commercialization infrastructure, and obesity-care delivery.
South Korea’s obesity burden and anti-obesity drug access issues are converging into a public-health and pricing story.
Body-composition monitoring is gaining relevance as GLP-1 use expands beyond weight loss alone.

📚 View the full Obesity archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What did Gan & Lee report for Insulin Ludefen (GZR4)?

Gan & Lee said once-weekly Insulin Ludefen met the primary endpoint in the China SUPER-3 Phase 3 trial and showed superior HbA1c reduction versus insulin glargine U100. [1]

Which companies are in the oral obesity-drug race covered by Reuters?

Reuters listed Novo Nordisk, Eli Lilly, Structure Therapeutics, Merck, AstraZeneca, Roche, Viking Therapeutics, Pfizer, Innovent Biologics, HuaDong Pharmaceutical, and Ascletis Pharma. [2]

What is InBody doing in China’s GLP-1 market?

InBody’s China unit is partnering with an undisclosed global pharma company to deploy body-composition analysis in pharmacy and hospital weight-management centers. [3]

What was reported about Innovent Biologics’ mazdutide?

China Daily reported JAMA publication of mazdutide data in Chinese adults with obesity, including mean weight reduction above 20% and cardiometabolic improvements. [4]

Why are illegal anti-obesity drug imports rising in South Korea?

Kyunghyang Shinmun linked the increase to price gaps for anti-obesity drugs such as Mounjaro between South Korea and overseas markets including Japan. [5]

What does the latest South Korea obesity report show?

KoreaBizwire reported that 34.4% of South Korean adults were obese in 2024, with the highest rates among men in their 30s and 40s. [6]

Entities / Keywords

Gan & Lee Pharmaceuticals, Insulin Ludefen, GZR4, SUPER-3, insulin glargine U100, Lantus, Bofanglutide
Novo Nordisk, Wegovy pill, oral semaglutide, Eli Lilly, Orforglipron, Foundayo, Zepbound
Structure Therapeutics, Aleniglipron, Merck, Hansoh Pharma, HS-10535
AstraZeneca, Eccogene, Elecoglipron, Roche, Carmot Therapeutics, CT-966
Viking Therapeutics, VK2735, Pfizer, Metsera, Sciwind Biosciences, Xianweiying, Danuglipron
Innovent Biologics, IBI3032, Mazdutide
InBody, InBody260S, GLP-1-linked weight management, China pharmacy franchise network
Korea Customs Service, Mounjaro, Wegovy, anti-obesity drug imports
Korea Disease Control and Prevention Agency, adult obesity, BMI 25